An additional 23 NSCLC patients had multiple BRAF alterations across functional classes (e.g., Class I and II, II and III), and these patients were counted as BRAF mutation positive in the overall analysis but excluded from individual BRAF class counts to avoid duplication. This evidence concerns the gene BRAF and non-small cell lung carcinoma.